A transportation network for human ovarian tissue is indispensable to success for fertility preservation
- 150 Downloads
The purpose of this study was to examine the efficacy of an ovarian tissue transportation network for fertility preservation (FP) for cancer patients in Japan.
PubMed was searched for papers on transportation of human ovarian tissue for FP. We analyzed population, area, number of cancer patients for ovarian tissue cryopreservation (OTC), quality control/assessment and safety, cost of a cryopreservation center for the building for 30 years, and medical fees of cancer patients (operation, cryopreservation, and storage of ovarian tissue).
More than twenty babies have been born in Denmark and Germany through a transportation system. Up to 400 new patients a year need OTC. The fees for removal, cryopreservation, and storage for 5 years, and transplantation of ovarian tissue are around €5,000, €4,000, and €5,000, respectively. It costs more than €5 million to establish and maintain one cryopreservation center for 30 years. If we have a few cryopreservation centers in Japan, we can cryopreserve 400 patients’ ovarian tissue per year by safer slow freezing and maintain quality control/assessment. We need to lighten the patients’ burden for easy to use FP by a government subsidy and medical insurance coverage.
This model has been termed the Danish model (“the woman stays - the tissue moves”). This is truly patient-centered medicine. We can have maximum effects with the minimum burden. A transportation network like those of Denmark and Germany is the best strategy for FP in Japan. It may be the best system for cancer patients, medical staff, and the Ministry of Health, Labor, and Welfare.
KeywordsFertility preservation Transportation Human ovarian tissue Cryopreservation Network
- 1.Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2016; DOI: https://doi.org/10.1007/s10815-016-0843-9.
- 3.Van der Ven H, Liebenthron J, Beckmann M, Toth B, Korell M, Krussel J, et al. Dittrich R on behalf of the FertiPROTEKT network. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31:2031–41.CrossRefPubMedGoogle Scholar
- 7.Kyono K. Fertility preservation:Transportation and cryopreservation of human ovarian tissue. 34th Annual meeting of Japan society of Fertilization and implantation. Super-hot topic2. Abstract 2016. p84.Google Scholar
- 8.CANCER STATISTICS IN JAPAN-2015; 82–83.Google Scholar
- 9.Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32:1–6.Google Scholar
- 16.Nishijima C, Iwahata H, Yoshioka N, Sugishita Y, Takae S, Horage Y, Kawamura K, Suzuki N. Oncofertility care of the St. Marianna University School of Medicine Hospital. The 4th World Congress of International Society for Fertility Preservation. 2015;Abstract A-010,166.Google Scholar
- 20.Kataoka A, Tokunaga E, Matsuda N, Shien T, Kawabata K, Miyashita M. Clinicopathological features of young patients (<35% years of age ) with breast cancer in a Japanese Breast Cancer Society supported study. Breast Cancer 2013 Apr 16.Google Scholar
- 26.von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011;284:427–35.CrossRefGoogle Scholar
- 47.Obata R, Nakamura Y, Okuyama N, Sasaki C, Ogura Y, Aono N, Hamano S, Hashimoto T, Kyono K. Comparison of residual dimethyl sulfoxide (DMSO) and ethylene glycol (EG) concentration in bovine ovarian tissue during warming steps between slow freezing and vitrification methods. 2017;P-513, The 33rd Meeting of the ESHRE.Google Scholar
- 48.Nakamura Y, Obata R, Okuyama N, Aono N, Hashimoto T, Kyono K. Residual ethylene glycol (EG) and dimethyl sulfoxide (DMSO) concentration in ovarian tissue during warming steps of vitrification protocol. Reprod Biomed Online. Online publication complete: 20-JUN-2017. DOI: https://doi.org/10.1016/j.rbmo.2017.05.016.
- 54.Directive 2011/24 EU of the European Parliament and of the Council of 9 March 2011 on the application of patents’ rights in cross-border healthcare.European Court of Human Rights. Case of S.H. and others v. Austria, 2011. http://cmiskp.echr.coe.int/tkp197/view.asp?action=html&documentld=894729portal=hbkm&source=extemalbydocnumber&table=F69A27FD8FB86142BF01c1166DEA398649. (26 November 2012, date last accessed).